BRAF and melanoma: In the IMspire150 trial, a combination of vemurafenib plus cobimetinib (Vem/Cobi), a BRAF/MEKi, and atezolizumab, an anti‐PD‐L1 antibody, was compared with Vem/Cobi in 514 treatment‐naïve patients with advanced BRAF V600‐mutant melanoma.